PTC Therapeutics is transitioning its growth engine from legacy drugs to new launches like Sephience, targeting rare genetic diseases with high unmet need. Pipeline catalysts, notably Votoplam for ...
The information above is compiled from the publicly available data on the MCA website. To confirm any details or get the latest status, please consult the official Ministry of Corporate Affairs (MCA) ...
WARREN, N.J. (AP) — WARREN, N.J. (AP) — PTC Therapeutics Inc. (PTCT) on Thursday reported a loss of $135 million in its fourth quarter. On a per-share basis, the Warren, New Jersey-based company said ...
With the writing apparently on the wall, PTC Therapeutics has called off its latest bid for FDA approval of its Duchenne muscular dystrophy (DMD) drug Translarna. Late Thursday, PTC revealed that it ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results